Rep. Lisa C. McClain Sells Off Shares of Amgen Inc. (NASDAQ:AMGN)

Key Points

• Representative Lisa C. McClain sold shares of Amgen Inc. for between $1,001 and $15,000 on September 25th, as disclosed in a filing on October 22nd.
• Amgen recently reported $6.02 EPS for the quarter, surpassing analysts' expectations, and projected fiscal year 2025 guidance between $20.200 and $21.300 EPS.
• The company announced a quarterly dividend of $2.38 per share, reflecting an annual dividend yield of 3.3% with a payout ratio of 77.84%.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Amgen Inc. NASDAQ: AMGN. In a filing disclosed on October 22nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on September 25th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of FMC NYSE: FMC on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Merit Medical Systems NASDAQ: MMSI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Darden Restaurants NYSE: DRI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Kenvue NYSE: KVUE on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Beacon Financial NYSE: BBT on 9/25/2025.
• Sold $1,001 - $15,000 in shares of British American Tobacco NYSE: BTI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Rollins NYSE: ROL on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of SAP NYSE: SAP on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of MGP Ingredients NASDAQ: MGPI on 9/25/2025.

Amgen Price Performance

Amgen stock opened at $292.89 on Friday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $335.88. The firm has a market capitalization of $157.68 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 2.62 and a beta of 0.49. The company has a fifty day simple moving average of $288.02 and a 200-day simple moving average of $287.23. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter in the previous year, the company posted $4.97 EPS. The company's revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were issued a dividend of $2.38 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.3%. Amgen's dividend payout ratio is presently 77.84%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares of the company's stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.76% of the company's stock.

Institutional Trading of Amgen

A number of large investors have recently made changes to their positions in AMGN. Wealth Quarterback LLC grew its position in shares of Amgen by 1.6% during the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company's stock worth $624,000 after acquiring an additional 34 shares during the last quarter. Fairvoy Private Wealth LLC grew its position in shares of Amgen by 1.1% during the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock worth $885,000 after acquiring an additional 35 shares during the last quarter. Nicholson Wealth Management Group LLC grew its position in shares of Amgen by 0.6% during the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after acquiring an additional 35 shares during the last quarter. LS Investment Advisors LLC grew its position in shares of Amgen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company's stock worth $250,000 after acquiring an additional 35 shares during the last quarter. Finally, Crown Wealth Group LLC grew its position in shares of Amgen by 4.0% during the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company's stock worth $257,000 after acquiring an additional 35 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Bank of America increased their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an "underperform" rating in a research report on Friday, September 26th. Morgan Stanley increased their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Raymond James Financial assumed coverage on shares of Amgen in a research report on Wednesday, September 3rd. They set a "market perform" rating on the stock. Citigroup increased their price target on shares of Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings raised shares of Amgen from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $300.94.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.